Laura has over 15 years of experience in business development, IP strategy, and deal structuring and negotiation in the biotech industry. She is currently the Vice President of Business Development at TriNetX, Inc., a venture-funded healthcare technology startup located in the Greater Boston area that focuses on developing a software platform leveraging patient data to improve clinical research, study design, and clinical trial recruitment activities. Prior to joining TriNetX, Laura was Director of Business Development Harvard University’s Office of Technology Development, and Director of Business Development at the Wyss Institute for Biologically Inspired Engineering at Harvard University where she took the lead in commercialization strategy, deal structuring, and negotiation. While at Harvard and Wyss, she led the evaluation, development, partnering and commercialization of innovations from a portfolio of over 250 biotech, synthetic chemistry, engineering, software, device, and stem cell technologies. Prior to Harvard, Laura worked in business development and IP strategy at Elixir Pharmaceuticals, Inc., and was CEO of Aferon, Inc., both early stage biotech companies in Cambridge, MA. She holds a BA in Philosophy and a BS in Biochemistry from the University of Missouri-Columbia, and a Ph.D. in Molecular Genetics and Cell Biology and an MBA from the University of Chicago Booth School of Business. She has co-authored several articles in peer reviewed journals such as Science and Cell and she is a registered patent agent.